Tsetsegsaikhan Batmunkh

Ulan Bator, Mongolia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Resilience to HPV vaccine safety scares in seven countries.

Resilience to HPV vaccine safety scares in seven countries.

Journal: Journal of global health

Published: May 29, 2026

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial.

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial.

Journal: Frontiers in immunology

Published: January 16, 2026

Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults.

Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults.

Journal: Frontiers in immunology

Published: January 02, 2026

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.

Journal: Vaccine

Published: February 18, 2025

Acceptance of Self-Sampling and Knowledge about Human Papillomavirus among Women in Mongolia.

Acceptance of Self-Sampling and Knowledge about Human Papillomavirus among Women in Mongolia.

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: January 23, 2024

Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.

Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.

Journal: The Lancet regional health. Western Pacific

Published: May 22, 2023

Translating Research to Action: The Development of a Pediatric Palliative Cancer Care Advocacy Tool in Eurasia.

Translating Research to Action: The Development of a Pediatric Palliative Cancer Care Advocacy Tool in Eurasia.

Journal: JCO global oncology

Published: January 27, 2022

Barriers to the early integration of palliative care in pediatric oncology in 11 Eurasian countries.

Barriers to the early integration of palliative care in pediatric oncology in 11 Eurasian countries.

Journal: Cancer

Published: May 18, 2020

A multicountry assessment in Eurasia: Alignment of physician perspectives on palliative care integration in pediatric oncology with World Health Organization guidelines.

A multicountry assessment in Eurasia: Alignment of physician perspectives on palliative care integration in pediatric oncology with World Health Organization guidelines.

Journal: Cancer

Published: December 02, 2019

Impact of tax increases on illicit cigarette trade in Mongolia.

Impact of tax increases on illicit cigarette trade in Mongolia.

Journal: Tobacco control

Published: December 20, 2018

Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia

Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia

Journal: Asian Pacific journal of cancer prevention : APJCP

Published: September 28, 2017

Health impact assessment in Mongolia: current situation, directions, and challenges.

Health impact assessment in Mongolia: current situation, directions, and challenges.

Journal: Asia-Pacific journal of public health

Published: August 14, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026